Key result
IV vernakalant yields ~2.5-fold higher odds of conversion to sinus rhythm vs. alternative antiarrhythmic drugs.
Why the study?
Vernakalant is an atrial-selective antiarrhythmic drug used for rapid conversion of recent-onset atrial fibrillation, but its effectiveness compared with alternative antiarrhythmic drugs remained uncertain.
Does intravenous vernakalant increase conversion to sinus rhythm compared to other antiarrhythmic drugs in adults with recent-onset atrial fibrillation?
Meta-Analysis (n=1,788)
Does intravenous vernakalant increase conversion to sinus rhythm compared to other antiarrhythmic drugs in adults with recent-onset atrial fibrillation?
Intravenous vernakalant achieves higher and faster conversion rates to sinus rhythm and reduces the need for electrical cardioversion compared to alternative antiarrhythmic drugs in recent-onset atrial fibrillation, though overall evidence certainty is low.
Answers are grounded in this paper and cite their sources.
Supports vernakalant for pharmacologic cardioversion in recent-onset AF; extends trial data via pooled efficacy estimates.
Vernakalant is an atrial-selective antiarrhythmic drug for the rapid conversion of recent-onset atrial fibrillation, but its effectiveness relative to alternative drugs remains uncertain. This systematic review and meta-analysis included studies comparing intravenous vernakalant with another antiarrhythmic drug in adults with recent-onset atrial fibrillation. PubMed, Embase, Scopus, and Web of Science were searched through March 2026. The primary outcome was conversion to sinus rhythm; secondary outcomes were time to conversion, electrical cardioversion, and adverse events. Random-effects models, trial sequential analysis, and GRADE were used. Nine studies (3 randomized, 1 quasi-randomized, and 5 observational; 1788 patients or episodes) compared vernakalant with amiodarone, ibutilide, flecainide, procainamide, or propafenone. Conversion occurred in 69.0% of patients receiving vernakalant and 53.0% of those receiving a comparator (odds ratio [OR], 2.52; 95% confidence interval [CI], 1.51-4.21; I2 = 72%). Heterogeneity was explained by the amiodarone comparisons (OR, 18.14; interaction P < 0.001); against the other comparators, the OR was 1.77 (95% CI, 1.41-2.22; I2 = 0%). Vernakalant shortened time to conversion among responders (mean difference, -19.3 minutes; 95% CI, -24.2 to -14.4) and reduced electrical cardioversion (OR, 0.50; 95% CI, 0.34-0.73), without a significant difference in adverse events (OR, 0.78; 95% CI, 0.57-1.08). The cumulative Z-curve crossed the trial sequential monitoring boundary, but the certainty of evidence was low for all outcomes.
No takes yet. Share an insight, caveat, or question.
Elawfi et al. (2026) conducted a meta-analysis in Recent-onset atrial fibrillation (n=1,788). Intravenous vernakalant vs. Alternative antiarrhythmic drugs (amiodarone, ibutilide, flecainide, procainamide, or propafenone) was evaluated on Conversion to sinus rhythm (OR 2.52, 95% CI 1.51-4.21). Intravenous vernakalant increased conversion to sinus rhythm compared with alternative antiarrhythmic drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: